Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma

NCT04460235 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Vaccine
Streptococcus Pneumoniae
Lymphoma, Non-Hodgkin

Interventions

BIOLOGICAL: Prevenar 13 + Pneumovax 23
BIOLOGICAL: PREVENAR20

Sponsor

Poitiers University Hospital